GlassScriptPhysician profile
Brian Clifford Badger
NPI 1912018433
$784.88
in general payments reported to CMS, 2019-2025
21 companies · $329 in 2025
The $329 reported for 2025 was more than what 87% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $109 · 2020: $68.11 · 2021: $77.37 · 2022: $87.45 · 2023: $71.78 · 2024: $42.45 · 2025: $329.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $443.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $87.59 | 2019-2023 | |
| Baxter Healthcare | $87.45 | 2022 | |
| Tris Pharma INC | $61.63 | 2019-2021 | |
| Insulet Corporation | $60.36 | 2025 | Omnipod |
| Takeda Pharmaceuticals U.S.A., INC. | $55.69 | 2019-2021 | |
| Neurelis, INC. | $52.35 | 2021-2023 | Valtoco |
| Merck Sharp & Dohme LLC | $43.35 | 2021-2024 | Vaxneuvance, Vaxelis, Gardasil 9 |
| Teva Pharmaceuticals USA, INC. | $39.08 | 2025 | Austedo Xr |
| Bayer Healthcare Pharmaceuticals INC. | $33.29 | 2025 | |
| Glaxosmithkline, LLC. | $32.34 | 2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $28.15 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $27.50 | 2024 | Caplyta |
| Vanda Pharmaceuticals INC. | $26.98 | 2025 | Fanapt, Hetlioz |
| Sanofi Pasteur INC. | $22.10 | 2023 | |
| Sanofi-Aventis U.S. LLC | $21.75 | 2025 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Azurity Pharmaceuticals, INC. | $19.26 | 2025 | |
| Sobi, INC | $18.43 | 2019 | |
| Novo Nordisk INC | $17.84 | 2025 | Wegovy |
| Phathom Pharmaceuticals, INC. | $17.55 | 2025 | Voquezna |
| Acadia Pharmaceuticals INC | $17.48 | 2025 | Daybue |
| Aimmune Therapeutics, INC. | $14.71 | 2025 | Zenpep |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Badger listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.